Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Andreas Pinter, Bernd Bonnekoh, Ina Marion Hadshiew & Sebastian Zimmer. (2019) Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clinical, Cosmetic and Investigational Dermatology 12, pages 509-517.
Read now
Read now
M Galluzzo, S D’Adamio, A Massaro, A Piccolo, L Bianchi & M Talamonti. (2019) Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. Clinical, Cosmetic and Investigational Dermatology 12, pages 311-321.
Read now
Read now
Luca Idolazzi. (2018) Secukinumab treatment in psoriatic patients: Italian experiences. Journal of Dermatological Treatment 29:sup1, pages 1-2.
Read now
Read now
M. Galluzzo, S. D’Adamio, E. Campione, S. Mazzilli, L. Bianchi & M. Talamonti. (2018) A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. Journal of Dermatological Treatment 29:sup1, pages 17-20.
Read now
Read now
M. Galluzzo, S. D’Adamio, E. Campione, L. Bianchi & M. Talamonti. (2018) A safety evaluation of guselkumab for the treatment of psoriasis. Expert Opinion on Drug Safety 17:7, pages 741-751.
Read now
Read now
M. Galluzzo, M. Talamonti, S. D’adamio & L. Bianchi. (2017) Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis. Expert Opinion on Drug Metabolism & Toxicology 13:6, pages 679-691.
Read now
Read now
Marco Galluzzo, Simone D’adamio, Luca Bianchi & Marina Talamonti. (2017) Tildrakizumab for treating psoriasis. Expert Opinion on Biological Therapy 17:5, pages 645-657.
Read now
Read now
Articles from other publishers (12)
Anuj Bhatnagar, Gautam Kumar Singh, Sanjeev Kumar Deshpande, Barnali Mitra, Debdeep Mitra, Vivek Agrawal, Suresh Reddy, Chetan Patil & Sunmeet Sandhu. (2023) Use of secukinumab in erythrodermic psoriasis: A single center experience. Medical Journal Armed Forces India 79, pages S6-S12.
Crossref
Crossref
Jiuping Zeng, Mingxing Li, Qianyun Zhao, Meijuan Chen, Long Zhao, Shulin Wei, Huan Yang, Yueshui Zhao, Anqi Wang, Jing Shen, Fukuan Du, Yu Chen, Shuai Deng, Fang Wang, Zhuo Zhang, Zhi Li, Tiangang Wang, Shengpeng Wang, Zhangang Xiao & Xu Wu. (2023) Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases. Journal of Pharmaceutical Analysis.
Crossref
Crossref
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini & Angelo Ruggiero. (2022) Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting. Dermatologic Therapy 35:9.
Crossref
Crossref
Bryan B. Fuller. 2022. Cosmetic Dermatology. Cosmetic Dermatology
366
387
.
Carmen RODRÍGUEZ-CERDEIRA, José L. GONZÁLEZ-CESPÓN, Erick MARTÍNEZ-HERRERA, Miguel CARNERO-GREGORIO, Adriana LÓPEZ-BARCENAS, Alexey SERGEEV & Ditte M. SAUNTE. (2021) Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Italian Journal of Dermatology and Venereology 156:5.
Crossref
Crossref
Chong Deng, Na Peng, Yuan Tang, Na Yu, Cuicui Wang, Xiaoyan Cai, Lijun Zhang, Dajun Hu, Francesco Ciccia & Liwei Lu. (2021) Roles of IL-25 in Type 2 Inflammation and Autoimmune Pathogenesis. Frontiers in Immunology 12.
Crossref
Crossref
Stanford Shoor. (2020) Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines. Infectious Disease Clinics of North America 34:2, pages 179-189.
Crossref
Crossref
Marco Galluzzo, Simone D'Adamio, Miriam Teoli, Luca Bianchi & Marina Talamonti. (2019) Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatologic Therapy 32:3.
Crossref
Crossref
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado & M. Fernández-Ruiz. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clinical Microbiology and Infection 24, pages S21-S40.
Crossref
Crossref
Rakeeb Kureshi, Michelle Bahri & Jamie B Spangler. (2018) Reprogramming immune proteins as therapeutics using molecular engineering. Current Opinion in Chemical Engineering 19, pages 27-34.
Crossref
Crossref
Ming Ji, Nina Xue, Fangfang Lai, Xiaoying Zhang, Sen Zhang, Yuchen Wang, Jing Jin & Xiaoguang Chen. (2018) Validating a Selective S1P<sub>1</sub> Receptor Modulator Syl930 for Psoriasis Treatment. Biological and Pharmaceutical Bulletin 41:4, pages 592-596.
Crossref
Crossref
Zeyu Chen, Yu Gong & Yuling Shi. (2017) Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis. Clinical Drug Investigation 37:10, pages 891-899.
Crossref
Crossref